November 2021: Pred kratkim se je začelo prvo klinično preskušanje domačega zdravljenja s himernimi antigenskimi receptorji T (CAR-T) naslednje generacije v Južni Koreji, ki je zasnovano za izogibanje signalom imunskih kontrolnih točk.
Korejski napredni inštitut za znanost in tehnologijo (KAIST) je v sredo objavil, da klinično preskušanje faze 1b njegove celične terapije CAR-T trenutno poteka v medicinskem centru Samsung v Seulu. Preskus poteka z 10 korejskimi bolniki, pri katerih se je difuzni velikocelični limfom B ponovil in je bil neodziven. Tržne pravice za plinovod so bile z univerze prenesene na podjetje Curocell, ki ga je soustanovil profesor Kim Chan-hyuk. Curocell je zadolžen za klinični razvojni program revolucionarja imunoterapija.
In addition, a Phase 2 klinično preskušanje involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for receptor himernega antigena T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Morda boste radi prebrali: CAR T-celična terapija v Koreji
Ugotovitve študije so bile predstavljene v članku, ki je bil objavljen na spletu v oktobrski številki Molecular Therapy.
